Research Topics
| M S TallmanSummaryAffiliation: Northwestern University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Hairy cell leukemia: towards a curative strategyAdi Gidron
Department of Medicine, Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, 676 North St. Clair, Suite 850, Chicago IL, 60611 USA
Hematol Oncol Clin North Am 20:1153-62. 2006..Fig. 1 is a suggested algorithm for the treatment of HCL. With the introduction of effective new agents, further studies will determine whether the now achievable prolonged survival will translate into cure...
Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort studyPriya P Gor
Center for Cancer and Hematologic Disease, 1930 E Route 70, Cherry Hill, NJ 08003, USA
Breast Cancer Res 12:R26. 2010..We hypothesize that functional single nucleotide polymorphisms (SNPs) in drug metabolizing enzymes (DMEs) that activate (CYPs) or metabolize (GSTs) cyclophosphamide account for some of the observed variability in disease outcomes...
What is the role of arsenic in newly diagnosed APL?Martin S Tallman
Northwestern University, Feinberg School of Medicine, Division of Hematology Oncology, Department of Medicine, 676 N St Clair Street, Suite 850, Chicago, IL 60611 2927, USA
Best Pract Res Clin Haematol 21:659-66. 2008..ATRA plus ATO has emerged as a promising strategy, even for those with high-risk disease. Future studies will compare ATRA and ATO to conventional ATRA and anthracycline-based chemotherapy...- The double hazard of thrombophilia and bleeding in acute promyelocytic leukemiaMartin S Tallman
Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois 60611, USA
Semin Thromb Hemost 33:330-8. 2007..The most important therapeutic strategy is early institution of ATRA at the first suspicion of the diagnosis (without waiting for genetic confirmation) and aggressive blood product support during induction... - All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocolMartin S Tallman
Northwestern University, Feinburg School of Medicine, Department of Medicine, Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA
Blood 100:4298-302. 2002..The improvement in outcome with ATRA in APL was maintained with long-term follow-up... - Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remissionMartin S Tallman
Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
Blood 110:409-17. 2007..However, treatment-related mortality was high. Matched unrelated donor HSCT should be considered for all patients with unfavorable cytogenetics who lack a suitable HLA-matched sibling donor... - Treatment of relapsed or refractory acute promyelocytic leukemiaMartin S Tallman
Northwestern University Feinberg School of Medicine, Division of Hematology Oncology, Robert H Lurie Comprehensive Cancer Center, 676 N St Clair Street, Suite 850, Chicago, IL 60611, USA
Best Pract Res Clin Haematol 20:57-65. 2007.... - Drug therapy for acute myeloid leukemiaMartin S Tallman
Northwestern University Feinberg School of Medicine, Division of Hematology Oncology, Robert H Lurie Comprehensive Cancer Center, 676 N St Clair St, Ste 850, Chicago, IL 60611, USA
Blood 106:1154-63. 2005.... - Treatment of patients with acute promyelocytic leukemia: a consensus statement on risk-adapted approaches to therapyMartin Tallman
Northwestern University Feinberg School of Medicine, 676 N St Clair, Chicago, IL 60611, USA
Clin Lymphoma Myeloma Leuk 10:S122-6. 2010..Expert opinions and evidence-based strategies presented during the roundtable are summarized herein... - Intravascular clotting activation and bleeding in patients with hematologic malignanciesMartin S Tallman
Division of Hematology Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois 60611, USA
Rev Clin Exp Hematol 8:E1. 2004..A number of medications have thrombogenic potential, including corticosteroids, thalidomide, L-asparaginase, all-trans retinoic acid and arsenic trioxide... - Immune therapy in haematological malignanciesMartin S Tallman
Northwestern University Feinberg, School of Medicine, Division of Hematology/Oncology, 676 North St. Clair Suite 850, Chicago, IL 60611, USA
Best Pract Res Clin Haematol 19:635-6. 2006 - Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancerMartin S Tallman
Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Chicago 60611, USA
N Engl J Med 349:17-26. 2003..High-dose chemotherapy with autologous hematopoietic stem-cell transplantation has been reported to be effective in the adjuvant setting for patients at high risk for relapse... - Long-term follow-up and potential for cure in acute promyelocytic leukaemiaMartin S Tallman
Division of Hematology Oncology, School of Medicine, Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg, 676 N St Clair, Suite 850, Chicago, IL 60611, USA
Best Pract Res Clin Haematol 16:535-43. 2003..These include the emergence of extramedullary disease, the development of secondary myelodysplasia or acute myeloid leukaemia and the potential for late-onset cardiac toxicity... - Meeting report. Acute promyelocytic leukemia-associated coagulopathy, 21 January 2004, London, United KingdomMartin S Tallman
Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Centre, 676 N St Clair Street, Suite 850, Chicago, IL 60611, USA
Leuk Res 29:347-51. 2005..Eight speakers participated in the workshop. This meeting report provides synopses of their presentations and a summary of highlights from the meeting... - Management of acute promyelocytic leukemiaMartin S Tallman
Division of Hematology Oncology, Northwestern University Medical School, Robert H Lurie Comprehensive Cancer Center, 676 N St Clair Street, Suite 850, Chicago, IL 60611, USA
Curr Oncol Rep 4:381-9. 2002..Incorporation of such agents into the treatment of patients with high-risk disease may be an important future direction to pursue... - Acute monocytic leukemia (French-American-British classification M5) does not have a worse prognosis than other subtypes of acute myeloid leukemia: a report from the Eastern Cooperative Oncology GroupMartin S Tallman
Northwestern University Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
J Clin Oncol 22:1276-86. 2004..This study was designed to compare the outcome of patients with M5 to that of other subtypes of AML, and to identify differences in M5a and M5b... - Historical aspects and milestones in the development of effective treatment for hairy cell leukemiaMartin S Tallman
Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA
Leuk Lymphoma 50:2-7. 2009..Immunoconjugate Therapy with BL22 (anti-CD22 [corrected] antibody linked to truncated to Pseudomonas exotoxin) represents the newest milestone in the development of effective treatment for hairy cell leukemia... - Hairy cell leukemia: survival and relapse. Long-term follow-up of purine analog-based therapy and approach for relapsed diseaseMartin S Tallman
Northwestern University Feinberg School of Medicine, Division of Hematology Oncology, Robert H Lurie Comprehensive Cancer Center, 676 N St Clair Street, Suite 850, Chicago, IL 60611, USA
Transfus Apher Sci 32:99-103. 2005..Relapse rates appear to be between 20% and 30%. Therapeutic strategies for patients with relapsed disease include retreatment with a purine analog, rituximab, or the anti-CD22 pseudomonas exotoxin A immunoconjugate, BL-22... - Acute promyelocytic leukemia: evolving therapeutic strategiesMartin S Tallman
Division of Hematology and Oncology, Robert H Lurie Comprehensive Cancer Center, Northwestern University Medical School, 676 N St Clair St, Suite 850, Chicago, IL 60611, USA
Blood 99:759-67. 2002..As experience with ATRA and arsenic trioxide in patients with APL accumulates, a number of important questions arise that need to be addressed... - How I treat acute promyelocytic leukemiaMartin S Tallman
Northwestern University Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
Blood 114:5126-35. 2009..Acute promyelocytic leukemia should be considered in any patient with newly diagnosed acute myeloid leukemia because the treatment is urgent and different from all other subtypes... - Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemiaM S Tallman
Department of Medicine, Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA
J Thromb Haemost 2:1341-50. 2004..However, our data also suggests that cytokine expression in some patients may be accelerated by either chemotherapy or ATRA. The implications of this observation for understanding the retinoic acid syndrome will require further studies... - The expanding role of arsenic in acute promyelocytic leukemiaMartin S Tallman
Feinberg School of Medicine, Department of Medicine, Northwestern University, Chicago, IL 60611 2927, USA
Semin Hematol 45:S25-9. 2008..High-risk patients continue to present a challenge, but a number of innovative agents and strategies are currently under active study... - Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially?J Mehta
The Feinberg School of Medicine, The Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA
Bone Marrow Transplant 38:95-100. 2006..This finding raises the question of whether a young 10-allele-matched unrelated donor is superior to an older matched sibling donor in patients where the clinical situation permits a choice between such donors... - Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndromeM S Tallman
Eastern Cooperative Oncology Group, Northwestern University Medical School, Robert H Lurie Comprehensive Cancer Center, Chicago IL 60611, USA
Blood 95:90-5. 2000..Two deaths were definitely attributable to the syndrome. No patient receiving ATRA as maintenance developed the syndrome. (Blood. 2000;95:90-95).. - Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantationS Singhal
The Feinberg School of Medicine, The Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA
Bone Marrow Transplant 37:553-7. 2006..We suggest using IBW rather than ABW to calculate cell doses for HSCT; for statistical analyses and for clinical practice if a specific cell dose is being targeted... - Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experienceM S Tallman
Northwestern University Medical School, Robert H Lurie Cancer Center, Chicago IL, USA
Blood 96:2405-11. 2000..4 months (range 1-160+ months). Although half of the patients achieved CR, the long-term outcome is extremely poor, primarily attributable to resistant disease. New therapeutic strategies are needed... - Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports projectC C Tigue
Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
Bone Marrow Transplant 40:185-92. 2007..There are questions about a causal relationship between G-CSF administration and acute leukemia, but more long-term safety data from database registries are needed to adequately evaluate such a relationship... - United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemiaS L Soignet
Leukemia and Developmental Chemotherapy Services, Department of Medicine, Memorial Sloan Kettering Cancer Center and Joan and Sanford Weill Medical College of Cornell University, New York, NY 10021, USA
J Clin Oncol 19:3852-60. 2001..To determine the safety and efficacy of arsenic trioxide (ATO) in patients with relapsed acute promyelocytic leukemia (APL)... - Molecular analysis and clinical outcome of adult APL patients with the type V PML-RARalpha isoform: results from intergroup protocol 0129J L Slack
Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
Blood 95:398-403. 2000..Blood. 2000;95:398-403).. - Current management and new approaches in the treatment of APLMartin S Tallman
Northwestern University, USA
Clin Adv Hematol Oncol 1:580-1. 2003 - Gemtuzumab ozogamicin (MylotargTM) is infrequently associated with sinusoidal obstructive syndrome/veno-occlusive diseaseC Nabhan
Oncology Specialists, S.C, Lutheran General Hospital Cancer Care Center, Park Ridge, IL, USA
Ann Oncol 15:1231-6. 2004..CONCLUSIONS: When administered using the recommended dose and schedule, GO has little association with VODSOS if given as a single agent. In this retrospective review, the incidence of GO-related SOSVOD is as low as 2%... - The role of bone marrow transplantation in acute promyelocytic leukemiaC Nabhan
Division of Hematology-Oncology, Department of Medicine, Northwestern University Medical School, Robert H Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
Bone Marrow Transplant 28:219-26. 2001..A randomized prospective clinical trial, or a retrospective analysis of the available data would be useful in answering this critical question... - Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphomaA M Evens
Division of Hematology Oncology, Hematopoietic Stem Cell Transplant Program and Lymphoma Program, Feinberg School of Medicine, Northwestern University, 676 North St Clair, Chicago, IL 60611, USA
Ann Oncol 18:679-88. 2007..We report the results of a prospective phase I/II clinical trial of accelerated hyperfractionated total lymphoid irradiation (TLI) immediately followed by high-dose chemotherapy for relapsed/refractory HL... - Use of total leukocyte and platelet counts to guide stem cell apheresis in healthy allogeneic donors treated with G-CSFM Tomblyn
The Hematopoietic Stem Cell Transplant Program, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
Bone Marrow Transplant 36:663-6. 2005..When blood counts do not meet these criteria, PBCD34 should be determined prior to initiation of apheresis... - Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) projectJune M McKoy
Division of Geriatric Medicine, Department of Medicine, Feinberg School of Medicine, Northwestern University, 303 E Chicago, Chicago, IL 60611, USA
Leuk Res 31:599-604. 2007.... - Splenectomy and treatments of historical interestAnaadriana Zakarija
Division of Hematology/Oncology, Medical School Robert H Lurie Comprehensive Cancer Center, Northwestern University, 676 N St Clair Street, Suite 850, Chicago, IL 60611, USA
Best Pract Res Clin Haematol 16:57-68. 2003..Splenectomy may be necessary in some instances. In this chapter the role of splenectomy is reviewed and other types of therapy of historical interest are presented... - New developments in antibody therapy for acute myeloid leukemiaMarcie R Tomblyn
Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA
Semin Oncol 30:502-8. 2003..GO is approved for relapsed disease in patients older than 60 years, but is being evaluated in combination with chemotherapy, in the setting of hematopoietic stem cell transplant, and in high-risk myelodysplasia... - Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experiencePunit Chadha
Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, 676 N St Clair St, Suite 700, Chicago, IL 60611, USA
Blood 106:241-6. 2005..There were 15 patients (17%) who developed other malignancies. Long-term follow-up of up to 14 years (median: 9.7 years) showed an excellent PFS and OS for HCL patients after 2-CdA treatment... - Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years oldSimrit Parmar
Division of Hematology-Oncology, Northwestern University, Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, 676 N St. Clair Street, Suite 850, Chicago, IL 60611, USA
Leuk Res 28:909-19. 2004..All subjects had progressive disease. There was no direct treatment-related mortality. Based on this study, we do not recommend single agent ATO as a treatment option for AML... - High-dose chemotherapy and autologous stem cell transplantation as treatment for high-risk breast cancerM S Tallman
Department of Medicine, Northwestern University Medical School, Robert H Lurie Cancer Center, Chicago, IL 60611, USA
Cancer Chemother Pharmacol 42:S60-7. 1998..Such issues, together with patient and physician bias regarding the benefits of this strategy, emphasize the need to complete the prospective randomized trials now underway... - New agents for the treatment of acute myeloid leukemiaMartin S Tallman
Northwestern University Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
Best Pract Res Clin Haematol 19:311-20. 2006..Additionally, evaluation of the identified prognostic factors and gene mutations will enable further pathologic classification of patients with AML... - IntroductionMartin S Tallman
Division of Hematology/Oncology, Northwestern University Medical School, Chicago, IL 60611, USA
Semin Hematol 39:1-2. 2002 - Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remissionMartin S Tallman
Northwestern University Medical School, Chicago, Illinois, USA
Biol Blood Marrow Transplant 12:204-16. 2006..Outcomes with standard-dose and high-dose cytarabine were similar. Based on our findings, we recommend that patients with AML in first remission receive consolidation before undergoing autotransplantation... - Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or olderChadi Nabhan
S.C. Lutheran General Hospital Cancer Care Center, Park Ridge, IL, USA
Leuk Res 29:53-7. 2005..These early results suggest that the option of single agent monoclonal antibody therapy is viable in this patient population and that additional studies are warranted with this agent either alone or in combination as initial therapy... - Negative regulatory effects of Mnk kinases in the generation of chemotherapy-induced antileukemic responsesJessica K Altman
Robert H Lurie Comprehensive Cancer Center, Division of Hematology Oncology, Northwestern University Medical School, Chicago, IL 60611, USA
Mol Pharmacol 78:778-84. 2010..They also identify this pathway as a novel target for the design of new approaches to enhance the antileukemic effects of chemotherapy or mTOR inhibitors in AML... - Acute lymphoblastic leukemia in a patient with chronic cyanoacrylate exposureBrian T Layden
Department of Internal Medicine, Northwestern University Medical School, Chicago, Ill, USA
Acta Haematol 118:242-3. 2007..This case raises the possibility that chronic exposure to cyanoacrylates, the adhesive agents in industrial strength glue, may be associated with the development of acute lymphoblastic leukemia in humans... - Strategies for the treatment of acute promyelocytic leukemiaOlga Frankfurt
Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine, Robert H Lurie Comprehensive Care Center of Northwestern University, 676 North St Clair Street, Suite 850, Chicago, IL 60611, USA
J Natl Compr Canc Netw 4:37-50. 2006..This article discusses the therapeutic interventions that transformed APL from one of the most lethal leukemias to one that is highly curable... - Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphomaJane N Winter
Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
J Clin Oncol 27:1653-9. 2009.... - Regulatory effects of mammalian target of rapamycin-mediated signals in the generation of arsenic trioxide responsesJessica K Altman
Robert H Lurie Comprehensive Cancer Center and Division of Hematology Oncology, Northwestern University Medical School, Lakeside Veterans Affairs Medical Center, Chicago, Illinois 60611, USA
J Biol Chem 283:1992-2001. 2008.... - Molecular characterization of acute myeloid leukemia and its impact on treatmentOlga Frankfurt
Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois 60611, USA
Curr Opin Oncol 19:635-49. 2007..This review outlines recent strides in our understanding of the molecular characteristics of acute myeloid leukemia... - Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturersCharles L Bennett
Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
Arch Intern Med 167:1041-9. 2007..We compare safety efforts for evaluating serious ADRs conducted by the FDA and pharmaceutical manufacturers vs the RADAR project... - Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) projectCharles L Bennett
VA Midwest Center for Health Services and Policy Research, the Jesse Brown VA Medical Center, Chicago, IL, USA
Br J Haematol 135:642-50. 2006..While a causal relationship with haematological malignancies cannot be demonstrated, long-term follow-up among healthy individuals who receive haematopoietic growth factors is needed... - Bleeding in acute leukemiaMartin S Tallman
Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
Pathophysiol Haemost Thromb 33:48-9. 2003 - G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysisAndrew M Evens
Division of Hematology Oncology, Lymphoma Program, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
Br J Haematol 137:545-52. 2007..0% and OS 91.3% (P = 0.46 and 0.67 respectively). Our experience suggests that ABVD may be safely and effectively administered at >99% dose-intensity without G-CSF support, regardless of the ANC... - Current treatment strategies for patients with hairy cell leukemiaMartin S Tallman
Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
Rev Clin Exp Hematol 6:389-400; discussion 449-50. 2002 - Growth factors in leukemiaOlga Frankfurt
Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois 60611, USA
J Natl Compr Canc Netw 5:203-15. 2007..Data from the published clinical trials do not seem to support emergence of drug-resistant leukemia, worsening toxicity, and bone marrow failure with growth factor administration... - A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphomaAndrew M Evens
Robert H Lurie Comprehensive Center of Northwestern University, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
Br J Haematol 140:385-93. 2008..001; OS P = 0.0002). CTAP/VMAC induction followed by consolidative auto-HSCT for newly diagnosed MCL is associated with high ORR and durable survival... - Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemiaCharles L Bennett
VA Chicago Healthcare System, Department of Medicine, Northwestern University Feinberg School of Medicine, and Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois 60611, USA
JAMA 299:914-24. 2008..Although systematic overviews of trials have identified venous thromboembolism (VTE) risks, none have identified mortality risks with ESAs... - Pure red-cell aplasia and epoetin therapyCharles L Bennett
MidWest Center for Health Services Research and Policy Studies, Jesse Brown Veterans Affairs Medical Center, Chicago, IL 60611, USA
N Engl J Med 351:1403-8. 2004.... - The Research on Adverse Drug Events and Reports (RADAR) projectCharles L Bennett
Jesse Brown VA Medical Center Mid West Center for Health Services and Policy Research, Chicago, Ill 60611, USA
JAMA 293:2131-40. 2005.... - Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) ProjectCharles L Bennett
MidWest Center for Health Services Research and Policy Studies, VA Chicago Healthcare System, Chicago, IL, USA
Blood 106:3343-7. 2005..Reinitiation of epoetin therapy among individuals could be considered if antierythropoietin antibodies are undetectable... - Early phase I/II trials with gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemiaChadi Nabhan
Division of Hematology and Oncology, Department of Medicine, Northwestern University Medical School, Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA
Clin Lymphoma 2:S19-23. 2002..This agent is currently being investigated in many clinical trials as a front-line approach in previously untreated individuals, and it is likely that it will have many more indications in the near future... - T-cell non-Hodgkin lymphomaMujahid A Rizvi
Division of Hematology Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, 676 N St Clair St, Ste 850, Chicago, IL 60611, USA
Blood 107:1255-64. 2006..Additional studies are required to learn more about the biology of these diseases, which may lead to more optimal and possibly targeted therapies... - Ideal or actual body weight to calculate CD34+ cell doses for autologous hematopoietic stem cell transplantation?M Y Ali
Hematopoietic Stem Cell Transplant Program, Division of Hematology Oncology, The Feinberg School of Medicine, Northwestern University, The Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA
Bone Marrow Transplant 31:861-4. 2003..These data show that the CD34+ cell dose based on IBW is a better predictor of neutrophil recovery after autotransplantation... - Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new eraChadi Nabhan
Oncology Specialists, S.C, Lutheran General Hospital Cancer Care Center, Park Ridge, IL, USA
Leuk Res 28:429-42. 2004..These drugs are increasingly used as initial therapy in CLL. Such strategies are associated with higher remission rates than have been previously achieved and in some cases, molecular remission, suggesting an important step towards cure... - Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic statusJohn L Frater
Department of Pathology, Northwestern Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
Am J Clin Pathol 119:833-41. 2003..Although all patients demonstrated an initial decrease in bone marrow cellularity after imatinib mesylate therapy, continued follow-up showed that histopathologic findings correlated with genetic response... - Autophagy is a critical mechanism for the induction of the antileukemic effects of arsenic trioxideDennis J Goussetis
Division of Hematology Oncology, Robert H Lurie Comprehensive Cancer Center, Northwestern University Medical School and Jesse Brown Veterans Affairs Medical Center, Chicago, Illinois 60611, USA
J Biol Chem 285:29989-97. 2010.... - Acute promyelocytic leukemia as a paradigm for targeted therapyMartin S Tallman
Department of Medicine, Northwestern University Feinberg School of Medicine, and Robert H Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
Semin Hematol 41:27-32. 2004..The targeted approach to treatment of this disease can serve as a paradigm for the treatment of other leukemias... - The potential of arsenic trioxide in the treatment of malignant disease: past, present, and futureAndrew M Evens
Department of Medicine, Divison of Hematology/Oncology, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, 676 N. St. Clair, Suite 850, Chicago, IL 60611, USA
Leuk Res 28:891-900. 2004..Continued study of As2O3 as a single-agent and in combination therapy will allow identification of the safest and most effective treatment regimens for malignant disease... - A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemiaMark A Weiss
Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Cancer 95:581-7. 2002..This regimen may be most suitable for patients who can undergo potentially curative allogeneic bone marrow transplantation if they achieve a complete response... - Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports projectLisa A Ladewski
Veterans Affairs Midwest Center for Health and Policy Research, Lakeside Division, Northwestern University Medical Center, Chicago, IL 60611, USA
J Clin Oncol 21:3859-66. 2003..This suggests a need for continued vigilance and efficient strategies for dissemination of information about ADRs associated with cancer drugs... - Activation of mammalian target of rapamycin and the p70 S6 kinase by arsenic trioxide in BCR-ABL-expressing cellsPatrick Yoon
Robert H. Lurie Comprehensive Cancer Center, 303 East Superior Street, Lurie 3-107, Chicago, IL 60611, USA
Mol Cancer Ther 5:2815-23. 2006.... - Cost analyses of adjunct colony stimulating factors for acute leukemia: can they improve clinical decision makingC L Bennett
Chicago VA Healthcare System Lakeside Division, and Northwestern University, Chicago, IL 60611, USA
Leuk Lymphoma 37:65-70. 2000..In studies of adult and older adult AML patients, both GM-CSF and G-CSF have clinical benefits and can be expected to lead to a decrease in overall costs... - Hairy cell leukemia presenting as localized skeletal involvementA Lal
Department of Pathology, Northwestern University Medical School, Feinberg Pavilion 7-209C, 251 E Huron Street, Chicago, IL 60611, USA
Leuk Lymphoma 43:2207-11. 2002..Skeletal involvement by HCL without co-existing bone marrow involvement should be included in the differential diagnosis of bone marrow lesions where metastatic tumor is the foremost consideration... - Angiogenesis in acute promyelocytic leukemia: induction by vascular endothelial growth factor and inhibition by all-trans retinoic acidA R Kini
Department of Pathology, Northwestern University Medical School, Chicago, IL, USA
Blood 97:3919-24. 2001..The addition of specific antiangiogenic agents to differentiation therapy or chemotherapy should be explored. (Blood. 2001;97:3919-3924).. - Retinoic acid syndrome: a problem of the past?M S Tallman
Division of Hematology Oncology, Northwestern University Medical School, and the Robert H Lurie Comprehensive Cancer Center, Chicago, IL, USA
Leukemia 16:160-1. 2002 - Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapyS M Trifilio
Department of Pharmacy, Division of Hematology Oncology, Northwestern Memorial Hospital, Chicago, IL, USA
Bone Marrow Transplant 39:425-9. 2007..Overall mortality was 73%. We conclude that zygomycosis after exposure to voriconazole is a recently described entity that is frequently fatal, despite treatment with currently available anti-fungal agents and surgery... - Secondary acute myelogenous leukemia with MLL gene rearrangement following radioimmunotherapy (RAIT) for non-Hodgkin's lymphomaC Nabhan
Division of Hematology Oncology, Department of Medicine, Northwestern University Medical School and The Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA
Leuk Lymphoma 43:2145-9. 2002..The patient was not exposed to topoisomerase II inhibitors. Our observations suggest a relationship between 11q23 leukemia and radioimmunotherapy (RAIT) and further studies are needed... - Relevance of pathologic classifications and diagnosis of acute myeloid leukemia to clinical trials and clinical practiceMartin S Tallman
Northwestern University, Feinberg School of Medicine, and Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, USA
Cancer Treat Res 121:45-67. 2004..Finally, microarray analysis will likely identify genes critically involved in the pathogenesis of specific pathologic subtypes... - Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cellsSimrit Parmar
Robert H. Lurie Comprehensive Cancer Center and Division of Hematology Oncology, Northwestern University Medical School, Chicago, Illinois 60611, USA
J Biol Chem 279:25345-52. 2004..They also suggest that, in addition to activation of mitogenic pathways, BCR-ABL promotes leukemogenesis by suppressing the function of growth inhibitory signaling cascades... - Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?Elizabeth A Richey
Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, 303 E Chicago Ave, Chicago, IL 60611, USA
J Clin Oncol 27:4398-405. 2009.... - Role of the p38 mitogen-activated protein kinase pathway in the generation of arsenic trioxide-dependent cellular responsesNick Giafis
Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Department of Medicine, Northwestern University Medical School, 303 East Superior Street, Chicago, IL 60611, USA
Cancer Res 66:6763-71. 2006..Altogether, our data indicate that the Mkk3/6-p38 signaling cascade is activated in a negative regulatory feedback manner to control induction of As(2)O(3)-mediated antileukemic effects... - Immunophenotypic variations in hairy cell leukemiaYi-Hua Chen
Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
Am J Clin Pathol 125:251-9. 2006..Recognizing the variability of immunophenotype and correlating with morphologic and clinical features are essential for establishing an accurate diagnosis of HCL... - Monoclonal antibodies for the treatment of acute myeloid leukemiaSyed A Abutalib
Section of Hematology and Oncology, University of Illinois at Chicago, Chicago, IL, USA
Curr Pharm Biotechnol 7:343-69. 2006..An additional strategy includes radiolabeled monoclonal antibodies to intensify the conditioning regimen prior to HSCT. The most promising results have been obtained with radiolabeled anti-CD45 antibodies... - Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxideJames L Slack
Department of Hematologic Oncology, Roswell Park Cancer Institute, Buffalo, New York, USA
Oncologist 7:1-13. 2002..The mechanism of action of ATO is also described in view of this agent's potential for broader therapeutic application in a variety of hematologic malignancies... - Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993Jacob M Rowe
Department of Hematology and Bone Marrow Transplantation, Rambam Medical Center and Technion, Israel Institute of Technology, Haifa 31096, Israel
Blood 106:3760-7. 2005..However, the achievement of CR within 4 weeks does not appear to be an independent prognostic factor... - Modified VAD and PSC-833 in the treatment of resistant or relapsing chronic lymphocytic leukemia (E4996): a trial of the Eastern Cooperative Oncology GroupWilliam R Friedenberg
Hematology Oncology, Guthrie Clinic, One Guthrie Square, Sayre, PA 18840, USA
Leuk Res 28:813-9. 2004..Laboratory tests to determine MDR and apoptosis proteins were correlated with response... - End points to establish the efficacy of new agents in the treatment of acute leukemiaFrederick R Appelbaum
Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Blood 109:1810-6. 2007..In this report, we present the results of that effort... - Arsenic trioxide: new clinical experience with an old medication in hematologic malignanciesDan Douer
University of Southern California Norris Comprehensive Cancer Center, 1441 Eastlake Ave, Rm 3460, Los Angeles, CA 90033, USA
J Clin Oncol 23:2396-410. 2005..This article reviews the clinical use of arsenic trioxide to date and discusses new therapeutic strategies evolving from its diverse biologic activities... - A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL)Chadi Nabhan
Oncology Specialists, S C Lutheran General Hospital Cancer Care Center, Park Ridge, Illinois 60068, USA
Leuk Lymphoma 45:2269-73. 2004..These studies are currently underway... - Chronic myelogenous leukemiaEllin Berman
J Natl Compr Canc Netw 3:732-55. 2005 - HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTRRichard F Schlenk
University of Ulm, Ulm, Germany
Biol Blood Marrow Transplant 14:187-96. 2008..These results suggest that patients with t(8;21) AML without poor prognostic factors have higher rates of survival after chemotherapy as a post remission therapy compared to HCT... - Intensified induction chemotherapy in adult acute myeloid leukemia followed by high-dose chemotherapy and autologous peripheral blood stem cell transplantation: an Eastern Cooperative Oncology Group trial (E4995)Peter A Cassileth
University of Miami Sylvester Comprehensive Cancer Center, Miami, FL 33136, USA
Leuk Lymphoma 46:55-61. 2005..Nevertheless, intensive post-remission therapy was well tolerated, no treatment-related mortality occurred with autologous PBSCT, and disease-free survival and overall survival were lengthy... - Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 studyAdele K Fielding
Royal Free and University College London Medical School, and Christie Hospital National Health Service Trust, Manchester, UK
Blood 109:944-50. 2007..Prevention of recurrence is the best strategy for long-term survival in this disease... - Utility of interphase FISH to stratify patients into cytogenetic risk categories at diagnosis of AML in an Eastern Cooperative Oncology Group (ECOG) clinical trial (E1900)Gail H Vance
Medical and Molecular Genetics, Indiana University School of Medicine, 975 W Walnut Street IB 264, Indianapolis, IN 46202, USA
Leuk Res 31:605-9. 2007.... - Comparison of interphase FISH and metaphase cytogenetics to study myelodysplastic syndrome: an Eastern Cooperative Oncology Group (ECOG) studyAthena M Cherry
Department of Pathology, Stanford Hospital and Clinics, Stanford, CA 94305, USA
Leuk Res 27:1085-90. 2003..In addition, it appears that interphase FISH studies are nearly as sensitive as cytogenetic analyses and can be a useful tool in studying bone marrow aspirates where cytogenetic analysis is not possible... - The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocationsFrederick R Appelbaum
Southwest Oncology Group Statistical Center, Seattle, WA, USA
Br J Haematol 135:165-73. 2006..021), and in patients with t(8;21) (P = 0.025). OS was superior in patients who received regimens with high-dose cytarabine, a combination of fludarabine and intermediate-dose cytarabine, or haematopoietic cell transplantation... - A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology GroupJacob M Rowe
Department of Hematology and Bone Marrow Transplantation, Rambam Medical Center and Technion, Haifa 31096 Israel
Blood 103:479-85. 2004..Priming with hematopoietic growth factor did not improve response when compared with placebo. Furthermore, delaying induction therapy in older adults may lead to a lower complete remission rate... - Established practice in the treatment of patients with acute promyleocytic leukemia and the introduction of arsenic trioxide as a novel therapyHerve Dombret
Department of Hematology, Hopital Saint Louis, Paris, France
Semin Hematol 39:8-13. 2002..Several prognostic factors have been defined in patients with APL, and it is possible that novel treatments such as ATO should be differentially applied to specific prognostic groups... - Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993Hillard M Lazarus
Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA
Blood 108:465-72. 2006..03) for those without. CNS leukemia in adult ALL is uncommon at diagnosis. Adult Ph-negative ALL patients, however, can attain long-term disease-free survival using SCT as well as conventional chemotherapy... - Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction: ECOG 3997Larry D Cripe
Indiana University Medical Center, Indianapolis, IN, United States
Leuk Res 30:823-7. 2006..I. 27-30 days) and 25 days (95% C.I. 24-29 days), respectively. The trial does not confirm the high CR rate observed in phase II trials, despite optimal supportive care...